No.
Indication
Patent
Filing Strategy
Development Progress
EG-501 is a small molecule tablet for the treatment of Cognitive Impairment (CI) in Neuropsychiatric Systemic Lupus Erythematosus (NPSLE). Systemic Lupus Erythematosus (SLE) is a debilitating autoimmune disorder with a wide array of etiologies and exacerbations. Cognitive impairment is one of the most common manifestations. Examples of cognitive dysfunction include fog, memory impairment, aphasia, trouble with verbal recall, and difficulty with concentration. 56% of SLE patient likely to experience CI over one year. There is currently no drug specific for the treatment of cognitive impairment in NPSLE patients worldwide.
EG-301 is used to treat patients over 50 years of age with dry age-related amacular degeneration (Dry AMD) with rapid progression. At this stage, presence of numerous medium-sized drusen or at least one large druse (diameter greater than 125 micrometers) Mild to moderate pigment changes in the retinal pigment epithelium Possible mild vision loss, but most individuals may not notice any significant symptoms.
EG-301 will be an oral dosage form that has been shown to be effective and safe in animal studies with fewer side effects. In 2020, there were about 100 million patients with macular disease worldwide, of which dry macular disease accounted for about 90%. There is an absolute global clinical need for dry macular disease. There are currently no drugs on the market to treat this disease, and the market size of its drugs is about US$60 - 90 billion.
EG-101 is an injectable drug used to treat preeclampsia. Preeclampsia, which affects 2% to 7% of pregnancies in developed countries, is a major clinical complication of maternal and infant mortality. It is characterized by hypertension, proteinuria, and damage to other organs, most commonly the liver and kidneys. The specific pathogenesis of preeclampsia is still unclear, and may be related to vascular endothelial dysfunction. There are currently no approved drugs on the market for the treatment and prevention of pre-eclampsia. EG-101 has shown good therapeutic effects in animal models of preeclampsia, with significant improvement in hypertension and proteinuria.
